Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardioprotection of SGLT2 inhibitors in elderly diabetes
jRCTs051190037Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luseogliflozin in type 2 diabetes mellitus (T2DM) and heart failure (HF), sponsored by Taisho Pharmaceutical. Started Jun 2020; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on jRCTs051190037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190037.